PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1575015
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1575015
Sentinel Node Biopsy Market size was valued at USD 720.98 Million in 2023, expanding at a CAGR of 7.10% from 2024 to 2032.
The Sentinel Node Biopsy Market focuses on a minimally invasive procedure used to determine if cancer has spread to the lymphatic system, specifically by identifying and removing the sentinel lymph node for examination. This market is witnessing strong growth due to increasing cancer prevalence and the rising adoption of sentinel node biopsies as a standard for detecting early-stage metastasis in cancers like breast cancer and melanoma. Technological advancements in biopsy techniques and imaging systems are also enhancing procedural accuracy. However, high costs and limited availability of specialized facilities in certain regions pose restraints. Opportunities lie in expanding access to affordable procedures and developing less invasive techniques to improve patient outcomes globally. For instance, according to the World Health Organization, over 2 million new breast cancer cases were reported in 2020, fueling demand for efficient diagnostic procedures like sentinel node biopsies.
Sentinel Node Biopsy Market- Market Dynamics
Rising Cancer Prevalence Drives Growth in the Sentinel Node Biopsy Market
The rising prevalence of cancer worldwide is significantly driving growth in the Sentinel Node Biopsy Market, as the procedure helps in early detection and precise staging of cancer. The World Health Organization (WHO) reports that cancer is one of the leading causes of death globally, making early intervention critical. Sentinel node biopsy, particularly in breast cancer and melanoma, allows for targeted removal of lymph nodes, reducing the need for extensive surgery. Various healthcare systems and organizations are increasing the adoption of this technique to improve patient outcomes. For instance, the National Cancer Institute (NCI) emphasizes the importance of sentinel node biopsy as a less invasive alternative for cancer staging. This growing demand for minimally invasive cancer diagnostic procedures continues to drive innovation and investment in this market.
Sentinel Node Biopsy Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.10% over the forecast period (2024-2032)
Based on Type segmentation, Sentinel Lymph Node Mapping was predicted to show maximum market share in the year 2023
Based on Procedure Type segmentation, Minimally Invasive was the leading type in 2023
Based on Indication segmentation, Breast Cancer was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Sentinel Node Biopsy Market is segmented on the basis of Type, Procedure Type, Indication, End-User, and Region.
The market is divided into four categories based on Type: Sentinel Lymph Node Mapping, Radiotracers, Blue Dyes, and Imaging Techniques. Sentinel Lymph Node Mapping is prioritized as the leading segment, followed by Radiotracers, which are widely used in conjunction with mapping techniques. Blue Dyes come next, while Imaging Techniques hold growing importance in the market.
The market is divided into two categories based on Procedure Type: Minimally Invasive, and Traditional Surgical Procedures. Minimally Invasive procedures are prioritized as the leading segment due to their reduced recovery time and patient preference. Traditional Surgical Procedures follow though they are gradually being replaced by more advanced, less invasive methods.
Sentinel Node Biopsy Market- Geographical Insights
North America leads the Sentinel Node Biopsy Market, driven by the high prevalence of cancer and advanced healthcare infrastructure. In the U.S., the National Cancer Institute (NCI) reports over 1.9 million new cancer cases annually, fueling the demand for early detection techniques like sentinel node biopsy. Europe follows closely, with countries like Germany and the U.K. adopting advanced biopsy techniques. For instance, the European Society of Breast Cancer Specialists (EUSOMA) has set guidelines promoting the use of sentinel node biopsy in breast cancer surgery. In Asia-Pacific, rising cancer cases and increasing healthcare investments are boosting market growth. China's National Cancer Center estimates over 4.5 million new cancer diagnoses annually, encouraging the adoption of advanced diagnostic tools. Meanwhile, in India, government initiatives like the National Programme for Prevention and Control of Cancer are raising awareness and improving access to biopsy procedures. These regional dynamics reflect the growing focus on cancer detection and treatment across key global markets.
Companies like Johnson & Johnson and Medtronic are actively involved in product development and strategic partnerships. For instance, in 2022, Johnson & Johnson's subsidiary, Ethicon, announced the launch of a new sentinel lymph node biopsy system, aimed at improving cancer diagnostics. Europe is also a prominent player, with key initiatives such as collaborations between healthcare institutions and biotechnology firms to advance biopsy technologies. In 2021, Sysmex Corporation partnered with Oxford University for research on advanced diagnostic tools. Asia-Pacific is experiencing a surge in partnerships and acquisitions, with companies like Fujifilm investing in cancer diagnostics. In 2023, Fujifilm announced its acquisition of a medical device firm specializing in biopsy technology, expanding its portfolio in the region. These strategic moves across regions highlight the competitive and innovation-driven nature of the market.
In April 2024, Hologic, Inc. announced its acquisition of Endomagnetics Ltd, a UK company specializing in breast cancer surgery technologies, for approximately USD 310 million. Endomagnetics offers innovative solutions like the Sentimag platform, Magseed marker, and Magtrace injectables.
In January 2024, Sahlgrenska University Hospital in Sweden concluded a clinical trial investigating ultra-low doses of superparamagnetic iron oxide nanoparticles for sentinel lymph node localization in breast cancer patients, with 220 individuals participating from January 2023 to January 2024.